natgillin/translations-raw huggingface dataset:
The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed, and 163 patients with mesothelioma randomised to receive single-agent cisplatin.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri > 5 % 168 bolnikov z mezoteliomom, ki so jih naključno razporedili, da so prejemali cisplatin in pemetreksed, ter pri 163 bolnikov z mezoteliomom, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri > 5 % od 265 bolnikov, ki so jih naključno razporedili, da so prejemali eno učinkovino pemetreksed z dopolniloma folno kislino in vitaminom B12, ter pri 276 bolnikih, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, docetaksel.
The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 265 patients randomly assigned to receive single-agent pemetrexed with folic acid and vitamin B12 supplementation, and 276 patients randomly assigned to receive single-agent docetaxel.
Spodnja preglednica podaja pogostnost in hudost neželenih učinkov, o katerih so poročali pri > 5 % od 265 bolnikov, ki so jih naključno razporedili, da so prejemali eno učinkovino pemetreksed z dopolniloma folno kislino in vitaminom B12, ter pri 276 bolnikih, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, docetaksel.
The table below provides the required volume of concentrate and the required volume of solvent to obtain the preferred injection volume of 0.1 ml/ kg fish, 0.2 ml/kg fish, 0.5 ml/kg fish or 1 ml/kg fish.
V tabeli sta navedena potrebna volumna koncentrata in vehikla za pripravo volumnov raztopine za injiciranje 0,1 ml/kg rib, 0,2 ml/kg rib, 0,5 ml/kg rib in 1 ml/kg rib.
The table below reflects the adverse reactions observed with mirabegron in the three 12-week phase 3 double blind, placebo controlled studies.
Spodnja preglednica prikazuje neţelene učinke, opaţene z zdravilom mirabegron v treh 12-tedenskih dvojno slepih, s placebom kontroliranih študijah 3. faze.
The table below reports adverse reactions by MedDRA system organ classes.
V spodnji preglednici so navedeni neželeni učinki, razvrščeni po organskih sistemih MedDRA.
The table below shows how often you will usually have this medicine.
V spodnji preglednici je prikazano, kako boste prejemali to zdravilo.
The table below shows how often you will usually have this medicine.
V spodnji preglednici je prikazano, kako pogosto boste običajno prejemali to zdravilo.
The table below shows how you will usually use this medicine.
Spodnja preglednica prikazuje, kako boste običajno uporabljali to zdravilo.
The table below shows the development of HIV-1 protease mutations and resistance to PIs in virologic failures at endpoint in the GS-US-216-130 trial.
Spodnja preglednica prikazuje razvoj mutacij zaviralcev proteaze HIV-1 in odpornost za PI pri bolnikih z virološko odpovedjo v preskušanju GS-US-216-130.
The table below shows the development of mutations and loss of susceptibility to PIs in virologic failures at endpoint in the ARTEMIS, ODIN and TITAN trials.
Spodnja preglednica prikazuje razvoj mutacij zaviralcev proteaze HIV-1 in zmanjšanje občutljivosti za PI pri bolnikih z virološko odpovedjo v preskušanjih ARTEMIS, ODIN in TITAN.
The table below shows the dose conversion (mg/ml) for the three oral syringes sizes.
Spodnja preglednica prikazuje pretvorbo odmerka (mg/ml) za tri velikosti brizg za peroralno dajanje.
The table below shows the dosimetry as calculated using the OLINDA (Organ Level INternal Dose Assessment) software.
V spodnji tabeli je prikazana dozimetrija, kot je izračunana z uporabo programske opreme OLINDA (Organ Level INternal Dose Assessment).
The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only.
Preglednica za hematološko toksičnost (preglednica 3) podaja shemo za prilagajanje odmerka, uporabljeno v kliničnih raziskavah le pri zdravljenju bolnic z rakom dojk ali rakom jajčnikov.
The table is based on adverse events reported during clinical trials and/or post-marketing use.
Preglednica temelji na neželenih dogodkih, o katerih so poročali med kliničnimi preskušanji in/ali uporabo v obdobju trženja.
The table lists adverse reactions according to system organ class and frequency: very common (≥1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100) and rare (≥1/10,000 to
Neželeni učinki so v preglednici navedeni glede organske sisteme in pogostost: zelo pogosti (≥1/10), pogosti (od ≥ 1/100 do <1/10), občasni (od ≥ 1/1,000 do <1/100) in redki (od ≥1/10,000 do <1/1,000).
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Neželeni učinki, navedeni v spodnji preglednici, so razvrščeni po organskih sistemih po klasifikaciji MedDRA (uporabljen je najustreznejši izraz po klasifikaciji MedDRA).
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Spodnja preglednica temelji na organskih sistemih po MedDRA (SOC – System Organ Class in ravni prednostnih izrazov).
The table provides a schedule assuring that the appropriate total daily dose of Viracept is taken each day based on the child’s weight.
Preglednica prikazuje načrt, ki zagotavlja, da otrok vsak dan dobi ustrezen celokupni dnevni odmerek zdravila Viracept glede na njegovo telesno maso.
The table reflects the frequency of ADRs during the chemotherapy phase of study treatment in which Portrazza+GC was directly compared with GC.
Tabela odraža pogostnost neželenih učinkov med fazo kemoterapije študijskega zdravljenja, v katerem so uporabo zdravila Portrazza+GC neposredno primerjali z uporabo GC.
The table summarizes ADRs (incidence above placebo and with a reasonable possibility of causality) from 512 patients treated with Plegridy 125 micrograms subcutaneously every 2 weeks and 500 patients who received placebo for up to 48 weeks.
V preglednici so povzeti neželeni učinki (incidenca večja kot pri placebu in z razumno možnostjo vzročne povezave) za 512 bolnikov, zdravljenih z zdravilom Plegridy 125 mikrogramov subkutano vsaka 2 tedna, in za 500 bolnikov, ki so placebo prejemali do 48 tednov.
The tablet also contains lactose monohydrate.
Zdravilo vsebuje laktozo monohidrat.
The tablet begins breaking up in the mouth within seconds and can then be swallowed with or without water.
Lahko jo pogoltnete z vodo ali brez nje.
The tablet can be divided into equal 50 mg doses.
Tableta se lahko deli na enaka 50 mg odmerka.
The tablet can be divided into equal doses.
Tableta se lahko deli na dva enaka odmerka.
The tablet can be divided into equal doses.
Tablete se lahko deli na enake odmerke.
The tablet can be divided into equal doses.
Tableto lahko razdelite na dva enaka odmerka.
The tablet can be divided into equal halves
Tableto lahko razdelimo na dva enaka odmerka.
The tablet can be divided into equal halves.
Tableta se lahko deli na enaki polovici..
The tablet can be divided into equal halves.
Tableta se lahko razdeli na dve enaki polovici.
The tablet can be divided into equal halves.
Tableto lahko razpolovimo na dve enaki polovici.
The tablet can be divided into four equal parts.
Tableta se lahko deli na štiri enake dele.
The tablet can be taken at any time of the day, however try to take your tablet at the same time each day.
Tableto lahko vzamete ob katerem koli času dneva, vendar jo po možnosti vzemite vsak dan ob istem času.
The tablet coating contains hypromellose; titanium dioxide (E171); talc; macrogol and red (60 and 180 mg tablets) or yellow (120 mg tablets) iron oxide (E172).
Obloga tablete vsebuje hipromelozo; titanov dioksid (E171); smukec; makrogol in rdeči (60 in 180 mg tablete) ali rumeni (120 mg tablete) železov oksid (E172).
The tablet coating is composed of: hypromellose, titanium dioxide, macrogols, hydroxypropyl cellulose, talc, colloidal anhydrous silica, polysorbate 80.
Sestavine filmske obloge so: hipromeloza, titanov dioksid, makrogoli, hidroksipropilceluloza, smukec, koloidni brezvodni silicijev dioksid, polisorbat 80.
The tablet coating is made of Opadry II butterscotsch 85F97369 (composed of polyvinyl alcohol partially hydrolysed, macrogol 3350, iron oxide yellow (E172), talc, titanium dioxide (E171) and iron oxide red (E172))
Obloga tablete vsebuje opadry II 85F97369, ki pa vsebuje polivinilalkohol delno hidroliziran, makrogol 3350, rumeni železov oksid (E172), smukec, titanov dioksid (E171) in rdeči železov oksid (E172).
The tablet coating is made of Opadry II butterscotsch 85F97369 (composed of polyvinyl alcohol partially hydrolysed, macrogol 3350, iron oxide yellow (E172), talc, titanium dioxide (E171) and iron oxide red (E172))
Obloga tablete vsebuje opadry II 85F97369, ki pa vsebuje polivinilalkohol delno hidroliziran, makrogol 3350, rumeni železov oksid (E172), smukec, titanov dioksid (E171), rdeči železov oksid (E172).
The tablet coating is made of red iron oxide (E172), yellow iron oxide (E172), macrogol, talc and hypromellose.
Obloga tablete je iz rdečega železovega oksida (E172), rumenega železovega oksida (E172), makrogola, smukca in hipromeloze.
The tablet core contains cellulose, microcrystalline (E460), lactose monohydrate, hypromellose (E464), sodium starch glycolate, magnesium stearate (E470b), anhydrous disodium phosphate (E339), ascorbyl palmitate (E304), disodium edetate and monobasic sodium phosphate (E339).
Jedro tablete vsebuje mikrokristalno celulozo (E460), laktozo monohidrat, hipromelozo (E464), natrijev škrobni glikolat, magnezijev stearat (E470b), brezvodni natrijev hidrogenfosfat (E339), askorbilpalmitat (E304), dinatrijev edetat in natrijev dihidrogenfosfat (E339).
The tablet core ingredients are: croscarmellose sodium, povidone K-30, colloidal anhydrous silica, magnesium stearate (E470b)
Sestavine jedra tablete so: premreženi natrijev karmelozat, povidon K-30, brezvodni koloidni silicij, magnezijev stearat (E470b)
The tablet film-coating contains polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc (E553b) and iron oxide yellow (E172, for 100 mg tablet) or iron oxide red (E172, for 500 mg tablet).
Filmska obloga vsebuje polivinilalkohol, titanov dioksid (E171), makrogol 3350, smukec (E553b) in rumeni železov oksid (E172, 100 mg tablete) ali rdeči železov oksid (E172, 500 mg tablete).
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Farmacevtska oblika tablete ni prilagojena za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Tablete niso primerne za zdravljenje dojenčkov in otrok, starih manj kot 6 let.
The tablet is 11.1 mm long and has a width of
Tableta je dolga 11,1 mm in široka 5,6 mm.
The tablet is a white, biconvex, round, film-coated tablet, with a diameter of 7.1 mm and a thickness of 2.7 mm, imprinted with ‘15’ on one side, and ‘102’ and ’15 mg’ on the other side, in grey ink.
Tableta je bela, bikonveksna, okrogla filmsko obložena tableta s premerom 7,1 mm in debeline 2,7 mm, s sivo oznako "15" na eni ter "102" in "15 mg" na drugi strani.
The tablet is beige, capsule-shaped, 21 mm in length, immediate-release, film-coated, and debossed with “CM” on one side and “551” on the other side.
Tableta s takojšnjim sproščanjem je bež, ovalna, dolga 21 mm, filmsko obložena z vtisnjeno oznako "CM" na eni in "551" na drugi strani.
The tablet is engraved with ‘S’ on one side.
V tableto je vtisnjena oznaka "S" na eni strani.
The tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed.
Tableto je treba vzeti enkrat na dan s tekočino, jo celo pogoltniti in se je ne sme zgristi, prelomiti ali zdrobiti.
The tablet may be crushed and mixed with water or a soft food such as applesauce immediately before you take it.
Tableto lahko tik pred uporabo zdrobite in zmešate z vodo ali mehko hrano, kot je na primer jabolčna čežana.
The tablet may be crushed and mixed with water or apple puree immediately before you take it.
Tableto lahko tik pred jemanjem zdrobite in premešate z vodo ali jabolčno čežano.
The tablet must be taken with food.
Tableto morate vzeti vsak dan s hrano.
The tablet should be dissolved in the mouth or in a drink.
Tableto raztopite v ustih ali pijači.
The tablet should be swallowed whole with a drink.
Tableto je treba pogoltniti celo skupaj s tekočino.
The tablet should be taken after the patient has not eaten anything for at least six hours overnight and at least 30 minutes before the first food or drink of the day.
Tableto mora bolnik vedno vzeti zjutraj na tešče, ko ni jedel vsaj šest ur, in vsaj 30 minut pred prvim obrokom ali pijačo.
The tablet should not be crushed.
Tablete ne sme zdrobiti.
The tablet should not be removed from the blister until ready to take it.
Bolnik ne sme vzeti tablete iz pretisnega omota, dokler ni pripravljen, da jo zaužije.
The tablet should not be stored once removed from the blister package as the tablet integrity can not be guaranteed and a risk of accidental exposure to a tablet can occur.
Tablete ni dovoljeno shranjevati zunaj pretisnega omota, saj se lahko razgradi, pojavi pa se lahko tudi tveganje nezgodne izpostavljenosti tableti
The tablet should not be stored once removed from the blister package as the tablet integrity can not be guaranteed and a risk of accidental exposure to a tablet can occur.
Tablete ni dovoljeno shranjevati zunaj pretisnega omota, saj se lahko razgradi, pojavi pa se lahko tudi tveganje nezgodne izpostavljenosti tableti.
The tablet strength depends on the patient’s treatment before starting Vokanamet.
Jakost tablete je odvisna od zdravljenja, ki ga je bolnik prejemal pred začetkom zdravljenja z zdravilom Vokanamet.
The tablet strength should be chosen according to the dog’s weight.
Izbrana jakost tablete je odvisna od telesne mase psa.
The tablets also contain lactose monohydrate.
Tablete vsebujejo tudi monohidrat laktoze.
The tablets also contain lactose.
Tableta vsebuje tudi laktozo.
The tablets also contain lactose.
Tablete vsebujejo tudi laktoze.
The tablets also contain Sunset Yellow (E110) as a colorant.
Tablete vsebujejo barvilo sončno rumeno FCF (E110).
The tablets also contain Sunset Yellow (E110) as a colourant
Tablete vsebujejo tudi barvilo sončno rumeno FCF (E110).
The tablets are brown coloured, palatable, oblong shaped with a score line and chewable.
Tablete so rjave, okusne, ovalne oblike, z zarezo in žvečljive.
The tablets are capsule shaped, biconvex, pink coloured and marked with ‘GXLL7’ on one side.
Tablete imajo obliko kapsule, so bikonveksne in rožnate ter na eni strani označene z oznako GXLL7.
The tablets are dissolved in water before the patient drinks the solution.
Bolnik naj tablete raztopi v kozarcu vode in nato spije raztopino.
The tablets are given once a day at the same time every day, at a dose of 1 mg per kilogram body weight with a range of 1-2 mg/kg in dogs or 1-2.4 mg/kg in cats.
Tablete se dajejo enkrat dnevno ob istem času vsak dan, in sicer v odmerku 1 mg na kilogram telesne mase v razponu 1–2 mg/kg pri psih oziroma 1–2,4 mg/kg pri mačkah.
The tablets are given once a day.
Tablete se dajejo enkrat na dan.
The tablets are given twice a day with or without food and usually 2 – 3 months is sufficient to control the condition although some dogs may need longer treatment.
Tablete se dajejo dvakrat na dan s hrano ali brez nje, dva- do trimesečno zdravljenje pa navadno zadostuje za nadzor nad motnjo, čeprav je za nekatere pse potrebno daljše zdravljenje.
The tablets are not intended to be split or broken into smaller pieces.
Tableta ni namenjena za deljenje ali drobljenje na manjše koščke.
The tablets are off-white, round and flat.
Tablete so sivo bele, okrogle in ploščate.
The tablets are packaged in HDPE bottles, each bottle containing 30 tablets with a cotton coiler and desiccant canister.
Tablete so pakirane v plastenke iz HDPE; ena plastenka vsebuje po 30 tablet, kosmič vate in sušilno sredstvo.
The tablets are packed in high density polyethylene bottles with a polypropylene cap and an induction seal.
Tablete so pakirane v polietilenske plastenke visoke gostote s polipropilenskim pokrovom in induktivno zvarjeno zaporko.
The tablets are pale brown-yellow, round, biconvex with bevelled edges and possible darker spots.
Tablete so bledo rjavo-rumene, okrogle, izbočene s posnetim robom in z možnimi temnejšimi pikami.
The tablets are pale brown-yellow, round, biconvex with bevelled edges and possible darker spots.
Tablete so bledo rjavo-rumene, okrogle, izbočene, s posnetim robom in z možnimi temnejšimi pikami.
The tablets are pink, marbled, round, biconvex with bevelled edges and possible darker spots.
Tablete so roza, marmorirane, okrogle, izbočene, s posnetim robom in z možnimi temnejšimi pikami.
The tablets are pink, marbled, round, biconvex with bevelled edges and possible darker spots.
Tablete so rožnate, marmorirane, okrogle, izbočene s posnetim robom in z možnimi temnejšimi pikami.
The tablets are printed with inks containing hypromellose (E464), propylene glycol, cochineal carminic acid (E120), indigo carmine (E132) and titanium dioxide (E171).
Filmsko obložene tablete so potiskane s črnili, ki vsebujejo hipromelozo (E464), propilenglikol, škrlatno karminsko kislino (E120), indigotin (E132) in titanov dioksid (E171).
The tablets are provided in a plastic bottle with a child-resistant closure.
Tablete so na voljo v plastenki z za otroke varno zaporko.
The tablets are provided in blister packs containing 2, 4, 8, or 12 tablets.
Tablete so na voljo v pretisnih omotih, ki vsebujejo 2, 4, 8 ali 12 tablet.
The tablets are provided in blister packs containing 4, 8, or 12 tablets.
Tablete so na voljo v pretisnih omotih, ki vsebujejo 4, 8 ali 12 tablet.
The tablets are provided in carton boxes with blisters containing 10,30 or 90 tablets.
Tablete so v kartonskih škatlah s pretisnimi omoti po 10, 30 ali 90 tablet.
The tablets are provided in UPVC/Monochlorotrifluorethylene blister packs containing 28 tablets.
Tablete so na voljo v pretisnih omotih iz UPVC/monoklorotrifluoretilena, ki vsebujejo 28 tablet.
The tablets are round (diameter 8 mm), convex and pink.
Tablete so okrogle (s premerom 8 mm), izbočene in rožnate.
The tablets are supplied in aluminium blister packs of 10, 30, 60 or 90 film-coated tablets.
Tablete so na voljo v aluminiastih pretisnih omotih, pakiranih po 10, 30, 60 ali 90 filmsko obloženih tablet.
The tablets are supplied in aluminium/aluminium blister packs of 14, 28, 30, 50, 56, 60, 90, 98 or 180 tablets.
Tablete so na voljo v pretisnih omotih iz aluminija/aluminija v pakiranjih po 14, 28, 30, 50, 56, 60, 90, 98 ali 180 tablet.
The tablets are supplied in Aluminium/aluminium blister packs of 14, 28, 30, 50, 56, 84, 90, 98,
Tablete so na voljo v aluminij/aluminij pretisnih omotih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali
The tablets are supplied in Aluminium/aluminium blister packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets or 50 x 1 tablets in Aluminium/aluminium perforated unit dose blisters.
Tablete so na voljo v aluminij/aluminij pretisnih omotih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet ali kot 50 x 1 tableta v aluminij/aluminij perforiranem pretisnem omotu za enkratni odmerek.
The tablets are supplied in blister packs of 30 and 100 tablets.
Tablete so v pretisnem omotu s 30 ali 100 tabletami.
The tablets are supplied in PA/Aluminium/PVC/Aluminium blister packs of 14, 28, 30, 50, 56, 90 or 98 tablets.
Tablete so na voljo v PA/aluminjastih/PVC/aluminjastih pretisnih omotih po 14, 28, 30, 50, 56, 90, ali 98 tablet.
The tablets are supplied in PA/Aluminium/PVC/Aluminium blister packs of 14, 28, 30, 50, 56, 90 or 98tablets.
Tablete so na voljo v PA/aluminijastih/PVC/aluminijastih pretisnih omotih po 14, 28, 30, 50, 56, 90 ali 98 tablet.
The tablets are supplied in PVC/PVDC/Aluminium blister packs of 14, 20, 28 or 56 tablets.
Tablete so na voljo v pretisnih omotih iz PVC/PVDC/aluminija po 14, 20, 28 ali 56 tablet.
The tablets are swallowed whole with a glass of water and must not be chewed.
Tablete je treba pogoltniti cele in jih poplakniti s kozarcem vode; nikakor se jih ne sme žvečiti.
The tablets are taken twice a day on days 1 to 5 and days 8 to 12 of each treatment cycle.
Tablete se jemljejo dvakrat na dan od 1. do 5. dneva in od 8. do 12. dneva vsakega cikla zdravljenja.
The tablets are taken with food.
Tablete se zaužijejo s hrano.
The tablets are used in children aged 6 years and above and weighing 25 kg or more.
Tablete se uporabljajo pri otrocih, starejših od šest let, ki tehtajo 25 kg ali več.
The tablets are white to off white, flat, round uncoated tablets with beveled edges debossed with ‘PIO’ on one side and ‘30’ on the other side.
Tablete so bele ali skoraj bele barve, ploščate, okrogle, neobložene tablete s poševnim robom, z oznako ‘PIO’ na eni in ‘30’ na drugi strani
The tablets are white to off white, flat, round uncoated tablets with beveled edges debossed with ‘PIO’ on one side and ‘45’ on the other side.
Tablete so bele ali skoraj bele barve, ploščate, okrogle, neobložene tablete s poševnim robom, z oznako ‘PIO’ na eni in ‘45’ na drugi strani
The tablets are white to off white, round, biconvex, uncoated tablets debossed with ‘P’ on one side and ‘15’ on other side.
Tablete so bele ali skoraj bele barve, okrogle, bikonveksne, neobložene tablete, z oznako 'P' na eni in '15' na drugi strani.
The tablets are white to off-white, oblong, film-coated, embossed ‘15 / 850’ on one face and ‘4833M’ on the other.
Tablete so bele ali skoraj bele barve, podolgovate, filmsko obložene, z oznako ‘15 / 850’ na eni in ‘4833M’ na drugi strani.
The tablets are white to off-white, of oval shape, and have a code embossed (one side with the code P12, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, ovalne in imajo vtisnjeno oznako (na eni strani je oznaka P12, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, of oval shape, and have a code embossed (one side with the code P13, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, ovalne in imajo vtisnjeno oznako (na eni strani je oznaka P13, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, of oval shape, and have a code embossed (one side with the code P3, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, ovalne in imajo vtisnjeno oznako (na eni strani je oznaka P3, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, of oval shape, and have a code embossed (one side with the code P4, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, ovalne in imajo vtisnjeno oznako (na eni strani je oznaka P4, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, of oval shape, and have a code embossed (one side with the code P5, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, ovalne in imajo vtisnjeno oznako (na eni strani je oznaka P5, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, of round shape, with bevelled edges, and have a code embossed (one side with the code P1, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, okrogle, z zaobljenim robom in imajo vtisnjeno oznako (na eni strani je oznaka P1, na drugi pa znak podjetja Boehringer Ingelheim).